Vjaivix Biosciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 15-12-2024
- Paid Up Capital ₹ 0.10 M
as on 15-12-2024
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.50 M
as on 15-12-2024
- Revenue -8.85%
(FY 2022)
- Profit 158.94%
(FY 2022)
- Ebitda 308.11%
(FY 2022)
- Net Worth 1.08%
(FY 2022)
- Total Assets -8.90%
(FY 2022)
About Vjaivix Biosciences
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.50 M.
Navya Kothagere, Sumathi Tmkur, Anuroop Chitradurga, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999KA2017PTC105337
- Company No.
105337
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Aug 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Vjaivix Biosciences Private Limited offer?
Vjaivix Biosciences Private Limited offers a wide range of products and services, including Fertilizers and Soil Additives, Nitrogen Fertilizers, Fertilizer.
Who are the key members and board of directors at Vjaivix Biosciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anuroop Chitradurga  | Director | 04-Aug-2017 | Current |
| Navya Kothagere | Director | 04-Aug-2017 | Current |
| Sumathi Tmkur | Director | 04-Aug-2017 | Current |
| Hemanth Mylanahalli | Director | 04-Aug-2017 | Current |
Financial Performance and Corporate Structure Insights of Vjaivix Biosciences.
Vjaivix Biosciences Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 8.85% decrease. The company also saw a substantial improvement in profitability, with a 158.94% increase in profit. The company's net worth moved up by a moderate rise of 1.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vjaivix Biosciences?
In 2019, Vjaivix Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 02 Aug 2018 | ₹0.50 M | Open |
How Many Employees Work at Vjaivix Biosciences?
Unlock and access historical data on people associated with Vjaivix Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vjaivix Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vjaivix Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
